Evidence map›Paper›PMID 37226249›Full record

ArticleThrombosis journal2023

Association between cancer history and second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry.

Tomoyo Hamana, Hiromasa Otake, Shoichi Kuramitsu, Tomohiro Shinozaki, Masanobu Ohya, Kazunori Horie, Hiroyoshi Kawamoto, Futoshi Yamanaka, Masahiro Natsuaki, Hiroki Shiomi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thrombosis journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tomoyo Hamana *Division of Cardiology, Department of Internal Medicine, Kobe University Graduates School of Medicine, Kobe, Japan.
Hiromasa Otake *Division of Cardiology, Department of Internal Medicine, Kobe University Graduates School of Medicine, Kobe, Japan.
Shoichi KuramitsuDepartment of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-Ku, Kitakyushu, 802-8555, Japan. kuramitsu@heart-kizuna.com.
Tomohiro ShinozakiDepartment of Information and Computer Technology, Faculty of Engineering, Tokyo University of Science, Tokyo, Japan.
Masanobu OhyaDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Kazunori HorieDepartment of Cardiovascular Medicine, Sendai Kousei Hospital, Sendai, Japan.
Hiroyoshi KawamotoDepartment of Cardiology, New Tokyo Hospital, Chiba, Japan.
Futoshi YamanakaDivision of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kanagawa, Japan.
Masahiro NatsuakiDepartment of Cardiovascular Medicine, Saga University, Saga, Japan.
Hiroki ShiomiDepartment of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Gaku NakazawaDepartment of Cardiology, Kindai University Faculty of Medicine, Osaka, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano, Kokurakita-Ku, Kitakyushu, 802-8555, Japan.
Kazushige KadotaDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Shigeru SaitoDivision of Cardiology and Catheterization Laboratories, Shonan Kamakura General Hospital, Kanagawa, Japan.
Takeshi KimuraDepartment of Cardiology, Hirakata Kohsai Hospital, Osaka, Japan.
REAL-ST Registry Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer-associated thrombosis is a frequent complication of cancer; however, little evidence is available regarding the association between cancer history and coronary artery stent thrombosis (ST). We aimed to investigate the relationship between cancer history and second-generation drug-eluting stent thrombosis (G2-ST).

methodsFrom the REAL-ST (Retrospective Multicenter Registry of ST After First- and Second-Generation Drug-Eluting Stent Implantation) registry, this study evaluated 1265 patients (G2- ST cases, n = 253; controls, n = 1012) with cancer-related information available.

resultsThe prevalence of patients with cancer history was higher (12.3% vs. 8.5%, p = 0.065), and that of currently diagnosed and currently treated cancer was significantly higher in ST cases than controls (3.6% vs. 1.4%, p = 0.021; 3.2% vs. 1.3%, p = 0.037, respectively). Multivariable logistic regression analysis revealed that cancer history was associated with late ST (odds ratio [OR]: 2.80, 95% confidence intervals [CI]: 0.92-8.55, p = 0.071) and very late ST (OR: 2.40, 95% CI: 1.02-5.65, p = 0.046), but not with early ST (OR: 1.01, 95% CI: 0.51-2.00, p = 0.97). During the median follow-up period of 872 days after the index ST events, patients with cancer history showed a higher mortality than those without, among both ST cases (hazard ratio [HR]: 1.93, 95% CI: 1.06-3.51, p = 0.031) and controls (HR: 1.93, 95% CI: 1.09-3.40, p = 0.023).

conclusionA post hoc analysis of REAL-ST registry revealed that patients with G2-ST had a higher prevalence of currently diagnosed and currently treated cancer. Notably, cancer history was associated with the occurrence of late and very late ST, but not with early ST.

Indexed as

Cancer-associated thrombosisDrug-eluting stentPercutaneous coronary interventionStent thrombosis

Identifiers

PMID37226249
PMCPMC10207799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.